임상 개발 성공 확률을 분석하는 제약 특화 AI 플랫폼

Unlearn.AI builds AI-generated digital twins of clinical trial participants — forecasts of how each individual patient's outcomes would evolve — and uses them to sharpen design, interim, and readout decisions in drug development.
월간 웹사이트 방문 수 추정치
이 도메인의 Similarweb 추정치이며 활성 사용자 수가 아닙니다. 관측 데이터가 있는 월만 표시하며 수집일과 집계 월을 구분합니다.
수집일 2026. 11. 11.

에디터가 매긴 5점 만점 평가이며, 사용자 평점의 평균이 아닙니다. 이 페이지의 관점들은 제품 정보를 바탕으로 AI가 정리한 것이며, 실제 사용자 후기가 아닙니다.
2026-11-11에 검증된 OpenAITools.app 텔레메트리에 따르면, Unlearn.AI(unlearn.ai)은(는) AI 헬스케어에 색인된 AI 플랫폼으로 월 1.71만회 방문을 기록 중이며, 전월 대비 트래픽 변화량은 -8.23천(-32.5%)입니다. 주요 지리적 시장은 미국(트래픽 점유율 69.4%)이며, 가격 문의 가격 모델로 운영됩니다. 월간 트래픽 기준 주요 경쟁 대안으로는 Intelligencia AI (월 3.87천회 방문), Cradle (월 1.7만회 방문), Floatz (월 253회 방문) 등이 있습니다.
임상시험 디지털 트윈 기술 덕분에 환자 모집 부담이 대폭 줄었습니다.
도입 비용이 높지만 통계적 유의성은 확실히 챙겨줍니다.
실제 사이트 점검, 요금 구조, 동일 카테고리 기준을 바탕으로 AI가 재구성한 참고 관점이며 개별 실사용자의 후기가 아닙니다.
Model-based forecasts of each participant's clinical outcomes, generated from baseline data already collected, that act as a virtual comparator or as additional information per enrolled patient.
A twin-based covariate adjustment approach that Unlearn describes as EMA-qualified and FDA-supported, used to reduce sample size in randomized controlled trials while maintaining power.
Build and compare design scenarios — endpoints, eligibility criteria, sample size, assumptions — so governance decisions are made with quantified tradeoffs instead of positions.
Pre-specified twin-based analyses added to the statistical analysis plan before unblinding, plus twin-adjusted analysis delivered at interim and at readout.
Design single-arm and externally controlled studies where randomization is not an option, selecting eligibility criteria that give open-label studies the best chance of a clear readout.
Unlearn.AI builds AI-generated digital twins of clinical trial participants — forecasts of how each individual patient's outcomes would evolve — and uses them to sharpen design, interim, and readout decisions in drug development.
Simulate expected enrollees against real eligibility criteria, then evaluate sample size and endpoints to lock in a smaller, lower-cost design before governance review.
Raise power at interim looks and in subgroup analyses without adding participants by incorporating twin-based covariate adjustment into the statistical analysis plan.
Re-analyze finished studies with digital twins to contextualize variability, improve endpoint sensitivity, and inform whether and how the program continues.
Use digital twins as the comparator in open-label or single-arm studies where randomization is impractical, tightening the evidence for regulators.
동일한 주요 카테고리에 속한 경쟁 AI 도구의 나란히 보는 텔레메트리 비교
| 순위 | AI 도구 | 월간 방문 수 | 전월 대비 성장률 | 직접 유입 비중 | 가격 | 일대일 비교 |
|---|---|---|---|---|---|---|
| ● | Unlearn.AI | 1.71만 | -32.5% | 직접 유입 44% | 가격 문의 | 현재 도구 |
| 1 | Intelligencia AI | 3.87천 | -31.9% | 직접 유입 27% | 가격 문의 | vs Intelligencia AI |
| 2 | Cradle | 1.7만 | -22.3% | 직접 유입 37% | 가격 문의 | vs Cradle |
| 3 | Floatz | 253 | -36.8% | 직접 유입 37% | 가격 문의 | vs Floatz |
| 4 | Delve AI | 4.9만 | -4.6% | 직접 유입 40% | 무료+유료 | vs Delve AI |
| 5 | Dr.Oracle | 72.38만 | -1.2% | 직접 유입 12% | 무료 체험 | vs Dr.Oracle |
| 6 | Aitia(gnshealthcare.com) | 0 | 0% | — | 가격 문의 | vs Aitia(gnshealthcare.com) |
임상 개발 성공 확률을 분석하는 제약 특화 AI 플랫폼
무료 / 오픈소스정신건강 전문가를 위한 AI 치료 노트와 AI 네이티브 EHR.
Sinkove generates synthetic biomedical images and anatomy data using AI, giving researchers and healthcare teams privacy-safe visual datasets to accelerate clinical research, model training and virtual trials.
Sinkove generates synthetic biomedical images and anatomy data using AI, giving researchers and healthcare teams privacy-safe visual datasets to accelerate clinical research, model training and virtual trials.
AI로 검진 대상자를 찾고 결절마다 위험 점수를 산출

무료 / 오픈소스디지털 트윈 사회 시뮬레이션으로 광고와 오디언스 인사이트 최적화
무료 / 오픈소스디지털 트윈 사회 시뮬레이션으로 광고와 오디언스 인사이트 최적화

RapidAI is an enterprise clinical AI platform that connects medical imaging to clinical decisions across neurology, cardiac and vascular care, trauma, emergency departments and oncology. Its FDA-cleared algorithms analyze CT, CT angiography, MRI and other scans to detect and quantify conditions such as large vessel occlusion stroke, aneurysms, aortic disease, pulmonary embolism, fractures and critical chest findings, then push the results to the care teams who need them. The Rapid Enterprise platform layers workflow integration, scalable infrastructure, data analytics and third-party partner AI on top of the core models, so health systems can run deep clinical AI across entire service lines rather than isolated point tools.
RapidAI is an enterprise clinical AI platform that connects medical imaging to clinical decisions across neurology, cardiac and vascular care, trauma, emergency departments and oncology. Its FDA-cleared algorithms analyze CT, CT angiography, MRI and other scans to detect and quantify conditions such as large vessel occlusion stroke, aneurysms, aortic disease, pulmonary embolism, fractures and critical chest findings, then push the results to the care teams who need them. The Rapid Enterprise platform layers workflow integration, scalable infrastructure, data analytics and third-party partner AI on top of the core models, so health systems can run deep clinical AI across entire service lines rather than isolated point tools.

무료 / 오픈소스January AI provides APIs and complete experiences that turn fragmented clinical, lifestyle and multi-omic data into personalized nutrition and metabolic intelligence, covering meal scanning, device-free glucose prediction and longitudinal health context.
무료 / 오픈소스January AI provides APIs and complete experiences that turn fragmented clinical, lifestyle and multi-omic data into personalized nutrition and metabolic intelligence, covering meal scanning, device-free glucose prediction and longitudinal health context.